Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on August 20, 2004, covering events that occurred on August 18, 2004. The filing addresses significant changes to the company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Executive Promotion: Susan Luscinski was promoted from Chief Financial Officer to the newly created position of Chief Operating Officer.
- New Appointment: Bryce Chicoyne was hired and appointed as the new Chief Financial Officer.
- Effective Date: Both leadership changes are scheduled to take effect on August 30, 2004.
Guidance, Outlook, and Risks
The filing contains a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to known and unknown risks. The company disclaims any obligation to update these statements. Specific risks are referenced as being detailed in the "Important Factors That May Affect Future Operating Results" section of the Annual Report on Form 10-K for the year ended December 31, 2003.
Investor Verification Checklist
- Verify the effective date of the leadership transition (August 30, 2004).
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for these changes.
- Consult the most recent Form 10-K for detailed financial metrics and risk factors not included in this 8-K.